Alfasigma | LinkedIn (original) (raw)

Chi siamo

Alfasigma è un'azienda farmaceutica internazionale fondata oltre 75 anni fa in Italia, dove ha sede (a Bologna e Milano). Il Gruppo opera in oltre 100 mercati in Europa, Nord e Sud America, Asia e Africa. Ha uffici in molti Paesi, tra cui Italia, Stati Uniti, Spagna, Germania, Messico e Cina; siti produttivi in Italia (Pomezia, RM; Alanno, PE; Sermoneta, LT; Trezzano Rosa, MI), in Spagna (Tortosa, Baix Ebre) e negli Stati Uniti (Shreveport, Louisiana) e laboratori di Ricerca & Sviluppo in Italia (Pomezia e Bergamo). In Alfasigma lavorano circa 4.000 persone impegnate in ricerca&sviluppo, produzione e distribuzione di farmaci, che contribuiscono alla sua mission di migliorare la salute e la qualità della vita di pazienti, caregiver e personale sanitario. L'azienda si concentra su tre aree terapeutiche principali: Gastroenterologia, Vascolare e Reumatologia. Il suo portfolio spazia dalle specialità da prescrizione, ai farmaci per le malattie rare ai prodotti di automedicazione inclusa la nutraceutica.

Settore

Fabbricazione di prodotti farmaceutici

Dimensioni dell’azienda

1001 - 5000 dipendenti

Sede principale

Bologna, BO

Tipo

Società privata non quotata

Settori di competenza

Farmaceutica, Ricerca & Sviluppo, Contract Manufacturing e API

Località

Dipendenti presso Alfasigma

Aggiornamenti

Here we are! #RISE GI – Research, Innovation, Science and Excellence in GastroIntestinal Care, Alfasigma’s 2025 Gastroenterology Standalone Event, has just concluded. International leading experts gathered to share cutting-edge research and best practices. The event focused on the global impact of deteriorating gastrointestinal health and the latest advances in microbiome research. Experts explored how unlocking the secrets of the gut microbiota is driving new microbiome-targeted approaches to prevent and treat GI diseases. The agenda also covered evolving care for patients with hepatic encephalopathy, IBS, and SUDD, unmet needs in GERD and constipation therapies, and the integration of cutting-edge technologies and personalized treatment strategies to optimize outcomes in both acute and chronic conditions. A pivotal moment for advancing precision medicine in gastrointestinal health #PharmaceuticalsWithPassion
142.621 follower
1 giorno
Relive key moments of the 2025 Alfasigma Vascular Endo-Exo Synergy (vEs) Standalone Event! From expert-led keynotes to meaningful scientific peer exchange, this event brought together leading international voices in vascular medicine to advance the dialogue on Chronic Venous Disease (CVD). In this video, international experts and members of the Alfasigma team reflect on the insights, collaboration and shared commitment that made this get together a landmark moment in vascular education. ▶️ Watch the video#PharmaceuticalsWithPassion
142.621 follower
4 giorni
The Annual Meeting of the European Venous Forum (EVF) has just come to a close! In was an exceptional opportunity to exchange knowledge and explore the latest scientific advances in the treatment of vascular diseases. This year’s discussions placed a strong emphasis on the management of Chronic Venous Disease (CVD), alongside practical updates in phlebology and real-world clinical applications. We are truly inspired by the collaborative spirit of the venous health community and remain committed to advancing patient care, from the early and moderate stages of CVD to the most severe cases.#PharmaceuticalsWithPassion #EVF2025
142.621 follower
1 settimana
🦠 Invisible, essential, and closer than we think: our microbiome is a complex world of microorganisms that helps regulate digestion, immunity and even mood. And most of them lives right in our gut. On #WorldMicrobiomeDay 2025, we join the global effort to raise awareness of these microscopic allies. This year’s theme “Microbiome 101: What You Need to Know” is a reminder that knowledge is the first step toward better health. At #Alfasigma, Gastroenterology has been at the core of our commitment. We are dedicated to supporting patients affected by gastrointestinal conditions where microbiota plays an essential role. We celebrate the extraordinary and still evolving science of the human microbiome: a complex ecosystem of microorganisms that live in symbiosis with the human body, performing crucial functions for our health.
142.621 follower
1 settimana
Our vascular educational journey has begun! Today, vascular medicine experts across the world have come together to explore the evolving landscape of Chronic Venous Disease (CVD), with particular focus on the critical role of endothelial dysfunction in patient outcomes. Through interactive sessions, participants delved into key aspects of CVD management—including risk factors, prevention and comprehensive treatment strategies. Starting from the evolving patients’ needs, this dynamic exchange of knowledge and collaboration is driving innovation and shaping the future of vascular care. A valuable opportunity to engage with peers and build meaningful new relationships with international leaders in the field. 📸 Swipe through the gallery for a snapshot of the day’s most relevant insights, international expert-led sessions, and scientific exchange. #PharmaceuticalsWithPassion
142.621 follower
1 settimana
🌍 Gastrointestinal diseases impact millions of people worldwide, ranging from functional GI disorders like Irritable Bowel Syndrome (IBS) and gastroesophageal reflux (GERD), to more complex conditions such as Inflammatory Bowel Disease (IBD), chronic liver disease and hepatic encephalopathy. * As part of our commitment to innovation and improving lives globally, we are proud to announce the first edition of #RISEGI: Research, Innovation, Science and Excellence in GastroIntestinal Care, Alfasigma’s 2025 Gastroenterology Standalone Event. Bringing together leading international experts in Madrid, this event will serve as a vibrant platform for the exchange of cutting-edge scientific insights and advancements in GI medical knowledge. 🔬 An inspiring program to advance the care and treatment of gastrointestinal diseases through cutting-edge research and collaboration. #PharmaceuticalsWithPassion*Source: https://lnkd.in/dy-Y-kAG
142.621 follower
2 settimane
We are pleased to announce our participation in the 25th Annual Meeting of the European Venous Forum (EVF), taking place in Krakow June 26 - 28, 2025! This meeting offers a valuable opportunity to connect with international experts and explore the latest developments in the diagnosis and treatment of Chronic Venous Disease (CVD). 📌 Don’t miss our dedicated symposium “Chronic Venous Disease: A Journey Through Complexities and Care” focused on the challenges associated with CVD. Our experts will explore the venous-arterial connection, share insights and interventions related to the disease progression and present clinical strategies to effectively address and manage CVD signs and symptoms in order to improve patient outcomes. 📅 Join us on Friday, June 27, 11:00 - 12:00 📍 Visit us at the booth n. #5 #PharmaceuticalsWithPassion #EVF2025
142.621 follower
2 settimane
At #EULAR2025 in Barcelona, Alfasigma’s presence went beyond simple participation. With five scientific abstracts and a Satellite Symposium featuring leading international experts, we are not just observing rheumatology’s future, we are shaping it together. Real impact for patients happens when expertise meets commitment. That is what Alfasigma stands for: to drive scientific exchange, deepen patient-centred innovation, and reinforce our unwavering dedication to advancing healthcare solutions that improve the lives of people with rheumatological diseases. We are grateful to everyone who is part of this journey. 🙏 A special thank you to all the colleagues and leading international experts who shared their experiences and insights in this video: Cameron Draper, Ida Guida, Philippe Guisset, Thijs Hendrikx, PhD, Joyce Hessen, Michele Manto, Yacin M., Elena Nikiphorou and Natalie Siegel. See you at EULAR 2026 in London
142.621 follower
3 settimane
🌍 Chronic Venous Disease (CVD) is a progressive condition that can significantly impact patients’ quality of life. The most common symptoms include pain, heaviness, a sensation of swelling, skin itching, cramps, and fatigue. Clinical signs may range from spider veins and varicose veins to edema, skin changes, and even venous ulcers in more advanced stage*. As part of our commitment to advancing vascular care, “Together We Advance. Vascular Endo-Exo Synergy (vEs)”, Alfasigma’s 2025 Vascular Standalone Event will bring together leading international experts to explore the full continuum of CVD management: from early detection and long-term prognosis to advanced treatment strategies and skin ulcer care. A full day of knowledge exchange, real-world learning and expert-driven discussions, focused on the latest clinical insights, trends and challenges shaping the future of chronic venous disease.#PharmaceuticalsWithPassion* De Maeseneer et al; Eur J Vasc Endovasc Surg (2022) 63, 184e267.
142.621 follower
3 settimane
Looking forward to #EULAR2025, starting tomorrow in Barcelona! We will be presenting five abstracts, including four on rheumatoid arthritis and one on axial spondylarthritis, demonstrating our dedication to advancing treatments for rheumatic diseases. 📍Don’t miss the chance to stop by Booth C1 and meet our team #EULAR2025

Alfasigma | LinkedIn (original) (raw)

Chi siamo

Località

Dipendenti presso Alfasigma

Aggiornamenti

Iscriviti ora per vedere cosa ti stai perdendo

Pagine affiliate

Pagine simili

Sfoglia le offerte di lavoro